Afuresertib vs NTQ1062
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: AKT (inhibitor) · full HR+/HER2- Metastatic Breast Cancer pipeline
Afuresertib
Developed by Laekna Limited under a licence from Novartis
NCT04851613 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked Phase 3 trial with 256 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-15. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Phase I: Overall Response Rate (ORR) based on RECIST 1.1 (Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)); Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by investigators (Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks for the first 12 months, then every 3 months through study completion): Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15). (met)
Result source: NCT04851613
NTQ1062
Developed by Sino Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07393321 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Afuresertib | NTQ1062 |
|---|---|---|
| PFS, median | —Trial running · NCT04851613 | —Trial running · NCT07393321 |
| OS, median | —Trial running · NCT04851613 | —Trial running · NCT07393321 |
| ORR | —Trial running · NCT04851613 | —Trial running · NCT07393321 |
| Clinical benefit rate | —Trial running · NCT04851613 | —Trial running · NCT07393321 |
PFS, median
- Afuresertib
- —Trial running · NCT04851613
- NTQ1062
- —Trial running · NCT07393321
OS, median
- Afuresertib
- —Trial running · NCT04851613
- NTQ1062
- —Trial running · NCT07393321
ORR
- Afuresertib
- —Trial running · NCT04851613
- NTQ1062
- —Trial running · NCT07393321
Clinical benefit rate
- Afuresertib
- —Trial running · NCT04851613
- NTQ1062
- —Trial running · NCT07393321
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NTQ1062: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afuresertib's landscape · NTQ1062's landscape